Efficacy and safety of upadacitinib in anti-TNF-refractory intestinal Behçet’s disease: a single-center retrospective study

Clicks: 12
ID: 328290
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #288 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To evaluate the efficacy and safety of upadacitinib in patients with anti-TNF -refractory intestinal Behçet's disease (BD). METHODS: We conducted a single-center retrospective study using data from a maintained BD registry at Peking Union Medical College Hospital between July 2024 and April 2026. Seventeen consecutive patients were included. Upadacitinib was initiated at a daily dose of 15 mg for all patients, with dose escalation to 30 mg in nine cases due to an inadequate response. The primary endpoint was a complete remission (CR) at Month 6, defined by a composite disease activity index incorporating global gastrointestinal (GI) symptom score and endoscopic evaluation. Secondary endpoints included changes in Disease Activity Index for Intestinal Behçet's Disease (DAIBD), inflammatory markers, glucocorticoid dosage, and safety. RESULTS: At Month 6, 50.0% (8/16) of patients who underwent endoscopy evaluation achieved CR based on the composite disease activity index. CR of global GI symptom score was observed in 76.5% (13/17) of patients and mucosal healing in 50% (8/16). Median DAIBD score decreased markedly from 55.0 (IQR 45.0-80.0) at baseline to 0.0 (IQR 0.0-10.0), accompanied by significant reductions in C-reactive protein and erythrocyte sedimentation rate. Upadacitinib demonstrated a glucocorticoid-sparing effect and was generally well tolerated. CONCLUSIONS: Upadacitinib represents a potential therapeutic option for patients with anti-TNF-refractory intestinal BD.
Reference Key
openalex_W7212052248 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jingwen Wu, Jianmei Wang, Xiaoyin Bai, Yeling Liu, Yiyuan Ao, Jinjing Liu, Hong Yang, Wenjie Zheng
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag489
URL
https://doi.org/10.1093/rheumatology/keag489
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.